Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 7/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | NOS1 | P29475 | 2/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 4/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16307680 | 0.93 | CYP1A2 (0.48) | CYP1A2CYP2A6MAPTALDH1A1TDP1 | |
| SCHEMBL28030111 | 0.79 | HSD17B10 (0.47) | CYP1A2MAPTALDH1A1TDP1TSHR | |
| SCHEMBL28030557 | 0.79 | MAPT (0.46) | CYP1A2MAPTALDH1A1TDP1TSHR | |
| SCHEMBL3829978 | 0.77 | TSHR (0.56) | MAPTALDH1A1TDP1TSHRCYP3A4 | |
| SCHEMBL14010958 | 0.76 | MAPT (0.53) | MAPTALDH1A1TDP1TSHRCYP3A4 | |
| SCHEMBL30095409 | 0.76 | MAPT (0.53) | MAPTALDH1A1TDP1TSHRCYP3A4 | |
| SCHEMBL28338203 | 0.75 | TSHR (0.54) | MAPTALDH1A1TDP1TSHRCYP3A4 | |
| SCHEMBL4535746 | 0.75 | SMN1; SMN2 (0.50) | CYP1A2MAPTALDH1A1TDP1TSHR | |
| SCHEMBL31155580 | 0.75 | SMN1; SMN2 (0.50) | CYP1A2MAPTALDH1A1TDP1TSHR | |
| SCHEMBL3190873 | 0.75 | MAPT (0.50) | CYP1A2MAPTALDH1A1TDP1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8980908-B2 | Non-peptidyl, potent, and selective mu opioid receptor antagonists and their use in treating opioid addiction and opioid induced constipation | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2015-03-17 | — | — | US | disclosed |
| US-8980908-B2 | Non-peptidyl, potent, and selective mu opioid receptor antagonists and their use in treating opioid addiction and opioid induced constipation | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2015-03-17 | — | — | US | disclosed |
| US-20140371255-A1 | NON-PEPTIDYL, POTENT, AND SELECTIVE MU OPIOID RECEPTOR ANTAGONISTS AND THEIR USE IN TREATING OPIOID ADDICTION AND OPIOID INDUCED CONSTIPATION | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2014-12-18 | — | — | US | disclosed |
| US-20140371255-A1 | NON-PEPTIDYL, POTENT, AND SELECTIVE MU OPIOID RECEPTOR ANTAGONISTS AND THEIR USE IN TREATING OPIOID ADDICTION AND OPIOID INDUCED CONSTIPATION | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2014-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140371255-A1 | NON-PEPTIDYL, POTENT, AND SELECTIVE MU OPIOID RECEPTOR ANTAGONISTS AND THEIR USE IN TREATING OPIOID ADDICTION AND OPIOID INDUCED CONSTIPATION | OPRM1, OPRK1, OPRL1 | CYP1A2 1578/4885CYP2A6 1995/4885MAPT 2460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.